These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Strategies for developing and commercializing nanobio drugs, diagnostics and devices. Bunger M Nanomedicine (Lond); 2007 Apr; 2(2):137-41. PubMed ID: 17716115 [No Abstract] [Full Text] [Related]
4. Can complexity be commercialized? Mack GS Nat Biotechnol; 2004 Oct; 22(10):1223-9. PubMed ID: 15470456 [No Abstract] [Full Text] [Related]
5. Sales from licensed and acquired products to increase by 2013. Goodman M Nat Rev Drug Discov; 2009 Jun; 8(6):443. PubMed ID: 19483704 [No Abstract] [Full Text] [Related]
6. Cost-effectiveness data on biologics needed. Sheridan C; Katsnelson A Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069 [No Abstract] [Full Text] [Related]
8. Trading on traditional medicines. Basu P Nat Biotechnol; 2004 Mar; 22(3):263-5. PubMed ID: 14990941 [No Abstract] [Full Text] [Related]
9. Biomanufacturing, from bust to boom...to bubble? Thiel KA Nat Biotechnol; 2004 Nov; 22(11):1365-72. PubMed ID: 15529157 [No Abstract] [Full Text] [Related]
10. Predictions and Statistics for the Best-Selling Drugs Globally and in the United States in 2018 and a Look Forward to 2024 Projections. Lindsley CW ACS Chem Neurosci; 2019 Mar; 10(3):1115. PubMed ID: 30889957 [No Abstract] [Full Text] [Related]
11. Assessment of the opportunities for pharmaceutical manufacturers in emerging markets. Anderson T; Olson J; Sobelman D J Manag Care Pharm; 2009 Jun; 15(5):396-402. PubMed ID: 19496636 [No Abstract] [Full Text] [Related]
15. How insurers' bargaining power affects drug prices in Medicare Part D. Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274 [No Abstract] [Full Text] [Related]
16. Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It? Hyman DA; Silver C J Leg Med; 2019; 39(2):137-149. PubMed ID: 31503533 [No Abstract] [Full Text] [Related]
17. Funding pharmaceutical innovation through direct tax credits. Lybecker KM; Freeman RA Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650 [TBL] [Abstract][Full Text] [Related]
18. Costing drug development. Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358 [No Abstract] [Full Text] [Related]
19. Pharmaceutical forecasting: throwing darts? Cha M; Rifai B; Sarraf P Nat Rev Drug Discov; 2013 Oct; 12(10):737-8. PubMed ID: 24080692 [No Abstract] [Full Text] [Related]
20. Market watch: Specialty pharmaceuticals to provide majority of sales by 2012. Goodman M Nat Rev Drug Discov; 2009 Mar; 8(3):184. PubMed ID: 19247297 [No Abstract] [Full Text] [Related] [Next] [New Search]